Teva Pharmaceutical Industries Ltd. announced the Food and Drug Administration approval of the first generic equivalent to Nexium (esomeprazole magnesium) Delayed-Release Capsules in the United States. Teva is preparing to launch the product in the near future. Nexium Delayed-Release Capsules, marketed by AstraZeneca, had annual sales of approximately $6 billion in the United States as of November 2014.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.28 USD | +1.05% | +5.37% | +65.52% |
Jul. 01 | Sector Update: Health Care Stocks Retreat Late Afternoon | MT |
Jul. 01 | Sector Update: Health Care Stocks Slipping in Afternoon Trading | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.52% | 19.57B | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+17.90% | 228B | |
+14.86% | 177B | |
+0.45% | 164B |
- Stock Market
- Equities
- TEVA Stock
- News Teva Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Limited Receives FDA Approval for First Generic Nexium® Delayed-Release Capsules in the United States